AC combination defined as either doxorubicin or epirubicin with cyclophosphamide, carmustine > 250 mg/m2, cisplatin, cyclophosphamide > 1,500 mg/m2, dacarbazine, doxorubicin ≥ 60 mg/m2or epirubicin >90 mg/m2, ifosamide > 2 gm/m2 per dose, mechlorethamine, streptozocin | High Emetic Risk >90% |
aldesleukin > 12-15 million IU/m2, amifostine > 300 mg/m2, arsenic trioxide, azacitidine, bendamustine, busulfan, carboplatin, carmustine ≤ 250 mg/m2, clofarabine, cyclophosphamide ≤ 1500 mg/m2, cytarabine > 200 mg/m2, dactinomycin, daunorubicin, doxorubicin <60 mg/ m2, epirubicin ≤ 90 mg/m2, idarubicin, ifosfamide <2 gm/m2 per dose, interferon alpha ≥ 10 million IU/m2, irinotecan, melphalan, MTX ≥250 mg/m2, oxaliplatin, temozolomide | Moderate Emetic Risk 30-90% |
ado-trastuzumab emtansine, amifostine ≤ 300 mg, aldesleukin ≤ 12 million IU/m2, brentuximab vedotin, cabazitaxol, carfilzomib, cytarabine (low dose) 100 - 200 mg/m2, docetaxel, doxorubicin (liposomal), eribulin, etoposide, 5-fluorouracil, floxuridine, gemcitabine, interferon alpha > 5 <10 million IU/m2, ixabepilone, MTX > 50 mg/m2 < 250 mg/m2, mitomcyin, mitoxantrone, omacetaxine, paclitaxel, paclitaxel-albumin, pemetrexed, pentostatin, pralatrexate, romidepsin,thiotepa, topotecan, ziv-aflibercept | Low Emetic Risk 10-30% |
alemtuzumab, asparaginase, bevacizumab, bleomycin, bortezomib, cetuximab, 2-chlorodeoxyadenosine (cladribine), cytarabine < 100 mg/m2, decitabine, denileukin diftitox, dexrazoxane, fludarabine, interferon alpha ≤ 5 million IU/m2, ipilimumab, MTX ≤ 50 mg/m2, nelarabine, ofatumumab, panitumumab, pegaspargase, peginterferon, pertuzumab, rituximab, temsirolimus, trastuzumab, valrubicin, vinblastine, vincristine, vincristine (liposomal), vinorelbine | Minimal Emetic Risk <10% |
altretamine, busulfan (≥ 4 mg/d), crizotinib, cyclophosphamide (≥ 100 mg/m2/d), estramustine, etoposide, lomustin (single day), mitotane, procarbazine, temozolomide (> 75 mg/m2/d), vismodegib | Emetogenic potential of oral antineoplastic agents: Moderate to High |
axitinib, bexarotene, bosutinib, busulfan (< 4 mg/d), cabozantinib, capecitabine, chlorambucil, cyclophosphamide (< 100 mg/m2/d), dasatinib, dabrafenib, erlotinib, everolimus, fludarabine, gefitinib, hydroxyurea, imatinib, lapatinib, lenalidomide, melphalan, mercaptopurine, methotrexate, nilotinib, pazopanib, pomalidomide, ponatinib, regorafenib, ruxolitinib, sorafenib, sunitinib, temozolomide (≤ 75 mg/m2/d), thalidomide, thioguanine, topotecan, trametinib, tretinoin, vandetanib, vemurafenib, vorinostat | Emetogenic potential of oral antineoplastic agents: Minimal to low |